EGFR and non-small cell lung carcinoma: Some studies also manifested that high-risk populations for CIP included those with NSCLC possessing sensitizing epidermal growth factor receptor (EGFR) mutation when treated with EGFR–tyrosine kinase inhibitor (TKI) in combination with ICIs, and those with an active lung infection (7, 19, 20).